27 related articles for article (PubMed ID: 17994630)
1. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice.
Bénard J; Da Silva J; De Blois MC; Boyer P; Duvillard P; Chiric E; Riou G
Cancer Res; 1985 Oct; 45(10):4970-9. PubMed ID: 3861241
[TBL] [Abstract][Full Text] [Related]
2. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.
Castells M; Milhas D; Gandy C; Thibault B; Rafii A; Delord JP; Couderc B
Cell Death Dis; 2013 Oct; 4(10):e887. PubMed ID: 24176845
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
[TBL] [Abstract][Full Text] [Related]
5. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
Landen CN; Goodman B; Katre AA; Steg AD; Nick AM; Stone RL; Miller LD; Mejia PV; Jennings NB; Gershenson DM; Bast RC; Coleman RL; Lopez-Berestein G; Sood AK
Mol Cancer Ther; 2010 Dec; 9(12):3186-99. PubMed ID: 20889728
[TBL] [Abstract][Full Text] [Related]
6. Proteomics and ovarian cancer: integrating proteomics information into clinical care.
Hays JL; Kim G; Giuroiu I; Kohn EC
J Proteomics; 2010 Sep; 73(10):1864-72. PubMed ID: 20561909
[TBL] [Abstract][Full Text] [Related]
7. Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer.
Lin B; White JT; Wu J; Lele S; Old LJ; Hood L; Odunsi K
Proteomics Clin Appl; 2009 Jul; 3(7):853-861. PubMed ID: 20559449
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.
Pan S; Cheng L; White JT; Lu W; Utleg AG; Yan X; Urban ND; Drescher CW; Hood L; Lin B
OMICS; 2009 Aug; 13(4):345-54. PubMed ID: 19422301
[TBL] [Abstract][Full Text] [Related]
9. Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.
Wang Y; Chiu JF
Met Based Drugs; 2008; 2008():716329. PubMed ID: 18670610
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Itamochi H; Kigawa J; Terakawa N
Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
[TBL] [Abstract][Full Text] [Related]
11. Technology insight: the application of proteomics in gastrointestinal disease.
Din S; Lennon AM; Arnott ID; Hupp T; Satsangi J
Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):372-85. PubMed ID: 17607293
[TBL] [Abstract][Full Text] [Related]
12. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment.
Le Moguen K; Lincet H; Marcelo P; Lemoisson E; Heutte N; Duval M; Poulain L; Vinh J; Gauduchon P; Baudin B
Proteomics; 2007 Nov; 7(22):4090-101. PubMed ID: 17994630
[TBL] [Abstract][Full Text] [Related]
13. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
[TBL] [Abstract][Full Text] [Related]
14. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].
Yan XD; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965
[TBL] [Abstract][Full Text] [Related]
15. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.
Yan XD; Pan LY; Yuan Y; Lang JH; Mao N
J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
